Cite
Laboratory and clinical studies of the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib in breast cancer
MLA
Leary, Alexandra. Laboratory and Clinical Studies of the Dual EGFR/HER2 Tyrosine Kinase Inhibitor Lapatinib in Breast Cancer. Jan. 2011. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsble&AN=edsble.538329&authtype=sso&custid=ns315887.
APA
Leary, A. (2011). Laboratory and clinical studies of the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib in breast cancer.
Chicago
Leary, Alexandra. 2011. “Laboratory and Clinical Studies of the Dual EGFR/HER2 Tyrosine Kinase Inhibitor Lapatinib in Breast Cancer,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsble&AN=edsble.538329&authtype=sso&custid=ns315887.